TG Therapeutics, a biotech firm focused on B-cell mediated diseases, continues to commercialize its FDA-approved MS treatment BRIUMVI in the U.S. and Europe, signaled by first-quarter 2026 filings showing progress toward profitability. The company is advancing a subcutaneous formulation of ublituximab in Phase 3 trials and expanding indications including myasthenia gravis and progressive MS. Despite these developments, TG Therapeutics faces constraints from competitive pressures, regulatory scrutiny on marketing practices, and debt covenants that limit strategic flexibility. Success hinges on sustained clinical outcomes, expanding market penetration, and effective execution of commercialization strategies.